Summary & Overview
HCPCS J1943: Injection, aripiprazole lauroxil (Aristada Initio), 1 mg
HCPCS Level II code J1943 denotes the injectable pharmaceutical product aripiprazole lauroxil (Aristada Initio), billed per 1 mg. This code is used when the medication product itself — supplied for initiation of long‑acting injectable antipsychotic therapy — is billed separately from the administration procedure. Nationally, accurate reporting of product codes like J1943 matters for clinical continuity, pharmacy inventory management, reimbursement alignment across payers, and specialty drug cost transparency.
Key payers in coverage analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J1943, notes on typical sites of service (outpatient and behavioral health settings), and what to expect in payer coverage and billing practice reviews. The publication outlines benchmarks where available, highlights relevant policy considerations for product billing versus administration, and provides coding context for integration with procedure and diagnosis reporting.
Data elements not provided in the input (such as associated taxonomies, ICD-10 pairings, and payer-specific reimbursement rates) are noted as unavailable and therefore excluded. The piece is intended as a national reference for health plan analysts, revenue cycle managers, and clinicians involved in long‑acting injectable antipsychotic initiation.
Billing Code Overview
HCPCS Level II code J1943 represents an injection formulation of aripiprazole lauroxil (Aristada Initio) measured per 1 mg unit. The code describes the pharmaceutical product administration item rather than the procedural administration service.
Service Type: Drug administration / injectable antipsychotic formulation
Typical Site of Service: Outpatient clinic, psychiatric clinic, or behavioral health facility where long-acting injectable antipsychotic initiation is performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 28-year-old adult diagnosed with schizophrenia or schizoaffective disorder presents to an outpatient behavioral health clinic for initiation of long-acting injectable antipsychotic therapy. The clinician elects to initiate aripiprazole lauroxil using the Aristada Initio protocol to rapidly achieve therapeutic plasma levels; the product is supplied as an initial 1 mg injection per the billing descriptor J1943. The clinic visit includes verification of diagnosis and indication, review of prior antipsychotic response and tolerability, assessment for contraindications (including hypersensitivity), confirmation of pregnancy status when applicable, medication counseling, and informed consent for long-acting injectable therapy.
The procedure is performed in a typical outpatient ambulatory behavioral health or psychiatric injection clinic room staffed by a licensed prescriber (psychiatrist, psychiatric nurse practitioner) and a registered nurse who prepares and administers the intramuscular injection. Post-injection observation for 15 to 30 minutes is documented for adverse reactions. Medication administration is documented in the medication administration record with lot number, expiration date, injection site, and patient response. Follow-up appointment scheduling for the next maintenance injection and coordination with pharmacy for specialty medication supply and prior authorization is completed before discharge.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |